These include antibody–drug conjugates (ADCs) that deliver NAMPT inhibitors specifically to cancer cells, as well as proteolysis-targeting chimera (PROTAC) technology NAMPT degraders that target both intracellular and extracellular forms of the enzyme [66,67]. This evidence concerns the gene NAMPT and cancer.